Establishment of parameters for optimal transduction efficiency and antitumor effects with purified high-titer HSV-TK retroviral vector in established solid tumors

Human Gene Therapy

Volumn 8, Issue 8, 1997, Pages 965-977

  Smiley, W Russell ^a   Laubert, Boris ^a,c   Howard, Bradley D ^a,d   Ibañez, Carlos ^a   Fong, Timothy C ^a   Summers, William S ^b   Burrows, Francis J ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CELERA   (United States)

^d UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; GANCICLOVIR; THYMIDINE KINASE; VIRUS ENZYME; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; FEMALE; GENE THERAPY; GENETIC TRANSDUCTION; HERPES SIMPLEX VIRUS; MOUSE; NONHUMAN; SOLID TUMOR; SUICIDE GENE; TUMOR MODEL;

EID: 0030918640     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1997.8.8-965     Document Type: Article

References (39)

1. ANDERSON, W.F. (1994). Editorial - Gene therapy for cancer. Hum. Gene Ther. 5, 1-2.
2. ARMENTANO, D., YU, S.-F., KANTOFF, P.W., VON RUDEN, T., ANDERSON, W.F., and GILBOA, E. (1987). Effect of internal viral sequences on the utility of retroviral vectors. J. Virol. 61, 1647-1650.
3. BARBA, D., HARDIN, J., SADELAIN, M., and GAGE, F. (1994). Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc. Natl. Acad. Sci. USA 91, 4348-4352.
4. BI, W.L., PARYSEK, L.M., WARNICK, R., and STAMBROOK, P.J. (1993). In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum. Gen. Ther. 4, 725-731.
5. BURNS, J.C., FRIEDMANN, T., DRIEVER, W., BURRASCANO, M., and YEE, J.-K. (1993). Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. USA 90, 8033-8037.
6. CHADA, S., DEJESUS, C.E., TOWNSEND, K., LEE, W.T.L., LAUBE, L., JOLLY, D.J., CHANG, S.M.W., and WARNER, J.F. (1993). Cross-reactive lysis of human targets infected with prototypic and clinical human immunodeficiency virus type 1 (HIV-1) strains by murine anti-HIV-1 IIIB env-specific cytotoxic T lymphocytes. J. Virol. 67, 3409-3417.
7. CHEN, S.H., CHEN, X.H., WANG, Y., KOSAI, K., FINEGOLD, M.J., RISH, S.S., and WOO, S.L. (1995). Combination gene therapy for liver metastases of colon carcinoma in vivo. Proc. Natl. Acad. Sci. USA 92, 2577-2581.
8. CORBETT, T.H., GRISWOLD, D.P, Jr., ROBERTS, B.J., PECKHAM, J.C., and SCHNABEL, F.M., JR. (1975). Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res. 35, 2434-2439.
9. CRYSTAL, R.G. (1995). Transfer of genes to humans: Early lessons and obstacles to success. Science 270, 404-410.
10. CULVER, K.W., RAM, Z., WALLBRIDGE, S., ISHII, H., OLDFIELD, E.H., and BLAESE, R.M. (1992). In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256, 1550-1552.
11. DONAHUE, R.E., KESSLER, S.W., BODINE, D., MCDONAGH, D., DUNBAR, C., GOODMAN, S., AGRICOLA, B., BYRNE, E., RAFFELD, M., MOEN, R., BACHER, J., ZSEBO, K.M., and NIENHUIS, A.W. (1992). Helper virus induced T cell lymphoma in non-human primates after retroviral mediated gene transfer. J. Exp. Med. 176, 1125-1135.
12. EASTHAM, J.A., CHEN, S.-H., SEHGAL, I., YANG, G., TIMME, T.L., HALL, S.J., WOO, S.L.C., and THOMPSON, T.C. (1996). Prostate cancer gene therapy: Herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum. Gene Ther. 7, 515-523.
13. ENQUIST, L.W., VANDE WOUDE, G.F., WAGNER, M., SMILEY, J.R., and SUMMERS, W.C. (1979). Construction and characterization of a recombinant plasmid encoding the gene for the thymidine kinase of herpes simplex type 1 virus. Gene 7, 335-342.
14. FORESTELL, S.P., BOHNLEIN, E., and RIGG, R.J. (1995). Retroviral end-point titer is not predictive of gene transfer efficiency: implications for vector production. Gene Ther. 2, 723-730.
15. FREEMAN, S.M., ABBOUD, C.N., WHARTENBY, K.A., PACKMAN, C.H., KOEPLIN, D.S., MOOLTEN, F.L., and ABRAHAM, G.N. (1993). The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53, 5274-5283.
16. GOLUMBEK, P.T., HAMZEH, F.M., JAFFEE, E.M., LEVITSKY, H., LIETMAN, P.S., and PARDOLL, D.M. (1992). Herpes simplex-1 virus thymidine kinase gene is unable to completely eliminate live, non-immunogenic tumor cell vaccines. J. Immunother. 12, 224-230.
17. HAMEL, W., MAGNELLI, L., CHIARUGI, V.P., and ISRAEL, M.A. (1996). Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells. Can. Res. 56, 2697-2702.
18. HWANG, L.-H.S., and GILBOA, E. (1984). Expression of genes introduced into cells by retroviral infection is more efficient than that of genes introduced into cells by DNA transfection. J. Virol. 50, 417-424.
19. IRWIN, M.S, LAUBE, L.S., LEE, V., AUSTIN, M., CHADA, S., ANDERSON, C.-G., TOWNSEND, K., JOLLY, D.J., and WARNER, J.F. (1994). Direct injection of a recombinant retroviral vector induces human immunodeficiency virus-specific immune responses in mice and non-human primates. J. Virol. 68, 5036-5044.
20. JAFFEE, E.M., DRANOFF, G., COHEN, L.K., HAUDA, K.M., CLIFT, S., MARSHALL, F.F., MULLIGAN, R.C., and PARDOLL, D.M. (1993). High efficiency gene transfer into primary human tumor explants without cell selection. Cancer Res. 53, 2221-2226.
21. JOLLY, D. (1994). Viral vector systems for gene therapy. Can. Gene Ther. 1, 51-64.
22. KOLBERG, R. (1992). Gene therapists test puzzling "bystander effect". J. Natl. Inst. Health Res. 4, 68-72.
23. LYONS, R.M., FORRY-SCHAUDIES, S., OTTO, E., WEY, C., PATIL-KOOTA, V., KALOSS, M., MCGARRITY, G.J., and CHIANG, Y.L. (1995). An improved retroviral vector encoding the herpes simplex virus thymidine kinase gene increases antitumor efficacy in vivo. Can. Gene Ther. 2, 273-280.
24. MILLER, A.D., JOLLY, D.J., FRIEDMANN, T., and VERMA, I.M. (1983). A transmissible retrovirus expressing human hypoxanthine phosphoribosyltransferase (HPRT): Gene transfer into cells obtained from humans deficient in HPRT. Proc. Natl. Acad. Sci. USA 80, 4709-4713.
25. MOOLTEN, F.L. (1986). Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Can. Res. 46, 5276-5281.
26. MOOLTEN, F.L. (1994). Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Can. Gene Ther. 1, 279-287.
27. MULLEN, C.A. (1994). Metabolic suicide genes in gene therapy. Pharmac. Ther. 63, 199-207.
28. PLAUTZ, G.E., YANG, Z.-Y., WU, B.-Y., GAO, X., and HUANG, L. (1993). Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc. Natl. Acad. Sci. USA 90, 4645-4649.
29. PURCELL, D.F.J., BROSCIUS, C.M., VANTN, E.F., BUCKLER, C.E., NIENHUIS, A.W., and MARTIN, M.A. (1996). An array of murine leukemia virus-related elements is transmitted and expressed in a primate recipient of retroviral gene transfer. J. Virol. 70(2), 887-897.
30. RAM, Z., CULVER, K.W., WALLBRIDGE, S., BLAESE, R.M., and OLDHELD, E.H. (1993). In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res. 53, 83-88.
31. RAM, Z., WALLBRIDGE, S., SHAWKER, T., CULVER, K.W., BLAESE, R.M., and OLDFIELD, E.H. (1994a). The effect of thymidine kinase transduction and GCV therapy on tumor vasculature and growth of 9L gliomas in rats. J. Neurosurg. 81, 256-260.
32. RAM, Z., WALLBRIDGE, S., OSHIRO, E., VIOLA, S., CHIANG, X., MUELLER, S.N., BLAESE, R.M., and OLDFIELD, E.H. (1994b). Intrathecal gene therapy for malignant leptomeningeal neoplasia. Cancer Res. 54, 2141-2145.
33. SHORT, M.P., CHOI, B.C., LEE, J.K., MALICK, A., BREAKEFIELD, X.O., and MARTUZA, R.L. (1990). Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line. J. Neuro. Res. 27, 427-433.
34. TAZZARI, P.L., GOBBI, M., DINOTA, A., BONTADINI, A., GRASSI, G., CERATO, C., CAVO, M., PILERI, S., CALIGARISCAPPIO, F., and TURA, S. (1987). Normal and neoplastic plasma cell membrane phenotype: Studies with new monoclonal antibodies. Clin. Exp. Immunol. 70, 192-200.
35. TEMIM, H.M. (1990). Safety considerations in somatic gene therapy of human disease with retrovirus vectors. Hum. Gene Ther. 1, 111-123.
36. TIMÁR, J., and KOVALSZKY, I. (1995). Differential expression of proteoglycans on the surface of malignant cells and in the tumor stroma. In Tumor Matrix Biology. R. Ádany, ed. (CRC Press, Inc., Boca Raton, FL) pp. 23-53.
37. VILE, R.G., NELSON, J.A., CASTLEDEN, S., CHONG, H., and HART, I.R. (1994). Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res. 54, 6228-6234.
38. WAGNER, M.S., SHARP, J.A., and SUMMERS, W.C. (1981). Nucleotide sequence of the thymidine kinase gene of herpes simplex virus type 1. Proc. Natl. Acad. Sci. USA 78, 1441-1445.
39. YANG, L., HWANG, R., PANDIT, L., GORDON, E.M., ANDERSON, W.F., and PAREKH, D. (1996). Gene therapy of metastatic pancreas cancer with intraperitoneal injection of concentrated retroviral herpes simplex thymidine kinase vector supernatant and ganciclovir. Ann. Surg. 224, 405-417.